Sequence not salvage.
Br J Haematol
; 204(5): 1590-1592, 2024 May.
Article
de En
| MEDLINE
| ID: mdl-38563345
ABSTRACT
Chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of multiple myeloma (MM) has fundamentally changed the relapsed and refractory therapeutic landscape, but the disease remains incurable. Two CAR-T products, idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti), have been FDA- and EMA-approved for the treatment of relapsed/refractory MM (RRMM); both target B-cell maturation antigen (BCMA), a surface glycoprotein highly expressed on MM cells. Despite deep and durable responses following CAR-T therapy, most patients will need subsequent treatment, and the optimal next-line therapy is presently unclear. Commentary on Liu et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy A retrospective analysis of LEGEND-2. Br J Haematol 2024;2041780-1789.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Immunothérapie adoptive
/
Thérapie de rattrapage
/
Myélome multiple
Limites:
Humans
Langue:
En
Journal:
Br J Haematol
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique